Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr
LIDDS carry out a directed share issue of and is provided with approximately MSEK 45 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr LIDDS carry out a directed share issue of and is provided with approximately MSEK 45 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer LIDDS avser att genomföra en riktad nyemission av aktier om cirka 45 Mkr LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules LIDDS CEO Interview with Finwire TV and Updated Company PresentationEvents
Company Analysis
Photo Library
Video Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comSubscribe for news
Press releases
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr LIDDS carry out a directed share issue of and is provided with approximately MSEK 45 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr LIDDS carry out a directed share issue of and is provided with approximately MSEK 45 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer LIDDS avser att genomföra en riktad nyemission av aktier om cirka 45 Mkr LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules LIDDS CEO Interview with Finwire TV and Updated Company Presentation
press
events
analysis
